Xcout Intel
OncoHost competitors & alternatives
The 12 closest competitors and alternatives to OncoHost among biotech companies — ranked by similarity to what OncoHost actually does, not by market-cap band.
Subscribe to see OncoHost’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About OncoHost
OncoHost is an Israeli precision-oncology biotechnology company that develops blood-based proteomic tests and computational analytics to characterize cancer patients and predict responses to immunotherapy. Its products are intended to help oncologists personalize treatment decisions and identify mechanisms of resistance, serving cancer patients, clinicians, pharmaceutical companies, and researchers.
OncoHost at a glance
OncoHost is a biotech company headquartered in Israel, founded in 2017. Xcout tracks 8 named people at OncoHost, including Ofer Sharon (CEO).
OncoHost leadership
- Ofer SharonCEO
- Moti HachamCFO
- Yehonatan ElonCTO
- Adam DickerChief Medical Officer
- Chris DingmanCCO
- Yuval ShakedCo-Founder & Chief Scientific Advisor
2 more named people on record for OncoHost, with roles, board committees and tenure — see the full roster →
Top 12 OncoHost competitors
Ranked by semantic similarity — how close each company is to OncoHost by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Impact Proteomics provides a proprietary antigen profiling and protein identification platform that analyzes patient samples to map disease-associated antigens without cloned intermediates. The company serves biotechnology and diagnostic partners by enabling target discovery, companion diagnostics development, and therapeutic selection for oncology and autoimmune diseases.
Healthcare & Cancer Diagnostics
Orchestra Health Technologies provides a platform combining proprietary software and care navigators to streamline the oncology diagnostic journey from biopsy to treatment decisions. The company serves cancer patients, oncologists, pathologists, and healthcare executives by coordinating pathology, molecular testing, and multi-disciplinary team workflows to accelerate precision medicine.
Biotechnology
Nexosome Oncology Holdings, Inc. develops blood tests for early-stage cancer detection using patented extracellular vesicle proteomics and AI/ML biomarker discovery. The company serves patients and healthcare partners by providing highly accurate diagnostic tools.
Medical Diagnostics, Biomedical Engineering, Liquid Biopsy
Nucleix is a liquid biopsy company headquartered in Rehovot, Israel. It aims to revolutionize cancer treatment through earlier disease detection, focusing on interventions that can bring the greatest impact.
Biotechnology
Predicta Biosciences is a precision oncology company that builds a molecular insights platform for blood cancer care. By utilizing a single blood sample, the company integrates multiomics and liquid biopsies to generate longitudinal genomic and immune insights for diagnostics.
Biotechnology
Olink Proteomics provides high-throughput protein biomarker analysis products, instruments, software, and analysis services for life science research and drug development. Utilizing its proprietary Proximity Extension Assay (PEA) technology and next-generation sequencing, the company serves researchers and pharmaceutical organizations focused on biomarker discovery and precision medicine.
Similar biotech company
Cofactor Genomics develops RNA-Seq technology and predictive diagnostics to help match cancer patients with appropriate immunotherapy treatments. The company offers tools such as the OncoPrism assay and collaborates with healthcare systems and clinical researchers to evaluate multidimensional biomarkers for various solid tumor cancers.
Biotechnology
Predicine Holdings Ltd provides next-generation liquid biopsy platforms and molecular profiling services for cancer research and precision medicine. The company utilizes proprietary blood- and urine-based assays to analyze circulating tumor DNA and RNA, serving biopharmaceutical partners and clinical researchers in oncology drug development and clinical trials.
Biotechnology
ImmunArray is a privately funded molecular diagnostics company co-located in Rehovot, Israel, and Richmond, Virginia. Founded in 2005, the company is dedicated to the development of novel blood-based tests and diagnostic solutions.
Similar biotech company
Precede Biosciences is a biotechnology company developing blood-based liquid-biopsy technologies for molecular profiling of cancer. Its tests are intended to support oncology research, precision treatment decisions, and pharmaceutical drug-development programs.
Biotech, Diagnostics
Novigenix is an immuno-transcriptomics and TechBio company that provides precision oncology solutions for biopharmaceutical companies and researchers. It offers LITOseek, an AI-powered liquid biopsy platform that analyzes gene activity in immune cells to support biomarker discovery, therapy development, and patient response monitoring.
Medical - Diagnostics & Research
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of OncoHost and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for OncoHostand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →